Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Yoshiki Ryoma"'
Autor:
Sadamu Homma, Yukiko Sagawa, Masato Okamoto, Hideo Komita, Yoshiki Ryoma, Eijiro Nagasaki, Shigeo Koido
Publikováno v:
Cancer Immunology, Immunotherapy. 56:1265-1274
Intratumoral (i.t.) injection of OK-432, a streptococcal preparation, into implanted tumors of mouse hepatocellular carcinoma (MIH-2) showed antitumor effect including tumor eradication. Intraperitoneal administration of same dose OK-432 did not exhi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32daa4e93a7fdcbb58ea7b995dc86e58
https://doi.org/10.1007/s00262-006-0277-9
https://doi.org/10.1007/s00262-006-0277-9
Autor:
Tomoyuki Tano, Motoo Saito, Mitsunobu Sato, Sharif Uddin Ahmed, Akiko Sasai, Yoshiki Ryoma, Masato Okamoto, Shin Kan, Yoichiro Moriya, Tetsuya Oshikawa
Publikováno v:
International Immunopharmacology. 6:764-773
We examined the role of nitric oxide (NO) induced by OK-432, a streptococcal immunotherapeutic agent, in anti-tumor effects of the OK-432 by in vitro and in vivo experiments using an NO synthase inhibitor, N-monomethyl-l-arginine acetate (NMA). The i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::624495ce7dc33b6cf7b105210f67c553
https://doi.org/10.1016/j.intimp.2005.11.010
https://doi.org/10.1016/j.intimp.2005.11.010
Autor:
Masato Okamoto, Yoichiro Moriya, Motoo Saito, Shizuo Akira, Mitsunobu Sato, Akiko Sasai, Yoshiki Ryoma, Tetsuya Oshikawa, Tomoyuki Tano, Shin Kan
Publikováno v:
Journal of Immunotherapy. 29:143-150
OK-432 is a Streptococcus-derived immunotherapeutic agent for malignancies. Our group has tried to identify the effective components of OK-432 and has succeeded in isolating a lipoteichoic acid-related preparation designated as OK-PSA, which is a str
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d29d012c8cfd480646f75aca601c2f0
https://doi.org/10.1097/01.cji.0000189028.18288.6f
https://doi.org/10.1097/01.cji.0000189028.18288.6f
Autor:
Shin Kan, Kensuke Miyake, Tomoyuki Tano, Motoo Saito, Tetsuya Oshikawa, Sharif Uddin Ahmed, Yoshiki Ryoma, Yoichiro Moriya, Akiko Sasai, Sachiko Akashi, Masato Okamoto, Mitsunobu Sato
Publikováno v:
Journal of Immunotherapy. 29:78-86
It has previously been reported by our group that Toll-like receptor (TLR) 4 is involved in anticancer immunity induced by OK-432, a Streptococcus-derived immunotherapeutic agent. However the detailed mechanism of the OK-432-induced immune response v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bea7264fe844af0529cd733e85251614
https://doi.org/10.1097/01.cji.0000192106.32206.30
https://doi.org/10.1097/01.cji.0000192106.32206.30
Autor:
Yuji Sato, Junichi Uchino, Yoshiki Ryoma, Shigechika Kohashi, Norihiko Takahashi, Kazuo Saito, Masao Kondo, Miyuki Matsuda, Satoru Todo, Ken-Ichi Ono, Toshiki Sinohara, Hiroshi Shiroto, Yukihumi Kondo, Syusaku Takahashi
Publikováno v:
Journal of Immunotherapy. 27:394-397
The effect of adjuvant immunochemotherapy including OK-432 (Picibanil) on survival was assessed in patients who underwent curative resection of gastric cancer. Patients enrolled in this randomized controlled study were randomly assigned to group A or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b6bb9451945337796c188e9cc507a13
https://doi.org/10.1097/00002371-200409000-00008
https://doi.org/10.1097/00002371-200409000-00008
Autor:
Hideo Yoshida, Sachiko Furuichi, Motoo Saito, Masato Okamoto, Sharif Uddin Ahmed, Yoshiki Ryoma, Tetsuya Oshikawa, Shuzo Matsubara, Hidetomo Nishikawa, Yoichiro Moriya, Mitsunobu Sato, Go Ohe
Publikováno v:
International Immunopharmacology. 3:643-655
We have previously isolated a lipoteichoic acid (LTA)-related molecule (OK-PSA) from OK-432, a streptococcal agent, by affinity chromatography on a CNBr-activated Sepharose 4B bound TS-2 monoclonal antibody (mAb) that neutralizes the interferon (IFN)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::718634c05a4a6c4334509be198b608dc
https://doi.org/10.1016/s1567-5769(02)00274-6
https://doi.org/10.1016/s1567-5769(02)00274-6
Autor:
Kazuo, Kasahara, Kazuhiro, Shibata, Hiromoto, Shintani, Kei-Ichi, Iwasa, Takashi, Sone, Hideharu, Kimura, Kouichi, Nobata, Tatsuki, Hirose, Yuzo, Yoshimi, Nobuyuki, Katayama, Yoshihisa, Ishiura, Toshiyuki, Kita, Koichi, Nishi, Yasuto, Nakatsumi, Yoshiki, Ryoma, Masaki, Fujimura, Shinji, Nakao
Publikováno v:
Anticancer research. 26(2B)
To determine the optimum dose of OK-432 for intrathoracic administration, a multicenter randomized phase II trial was conducted in patients with malignant pleural effusion due to non-small cell lung cancer. Patients with histologically- or cytologica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::eff7e4e3a2db5bb5f55ad20b7b5b9ee5
https://pubmed.ncbi.nlm.nih.gov/16619563
https://pubmed.ncbi.nlm.nih.gov/16619563
Autor:
Akiko Sasai, Shin Kan, Sharif Uddin Ahmed, Tomoyuki Tano, Hideki Ohue, Masato Okamoto, Motoo Saito, Mitsunobu Sato, Tetsuya Oshikawa, Yoichiro Moriya, Tokafumi Hiroshima, Yoshiki Ryoma
Publikováno v:
Journal of immunotherapy (Hagerstown, Md. : 1997). 27(6)
The authors investigated the in vivo anti-tumor effect of intratumoral administration of bone marrow-derived dendritic cells (DCs) after chemotherapy using an oral fluoropyrimidine anti-cancer drug TS-1, and followed by immunotherapeutic agent OK-432
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b7a21121a1ae4dec467037528c1af73
https://pubmed.ncbi.nlm.nih.gov/15534487
https://pubmed.ncbi.nlm.nih.gov/15534487
Autor:
Yoshiki, Ryoma, Yoichiro, Moriya, Masato, Okamoto, Isao, Kanaya, Motoo, Saito, Mitsunobu, Sato
Publikováno v:
Anticancer research. 24(5C)
OK-432 (Picibanil), a streptococcal preparation with potent biological response modifying activities, was approved in Japan as an anticancer agent in 1975. In the ensuing 30 years, since then, a significant amount of data, including clinical as well
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1139457374d3cedb4c16950c7057ac89
https://pubmed.ncbi.nlm.nih.gov/15515424
https://pubmed.ncbi.nlm.nih.gov/15515424
Autor:
Yoichiro Moriya, Shizuo Akira, Motoo Saito, Sharif Uddin Ahmed, Hidetomo Nishikawa, Tomoyuki Tano, Kensuke Miyake, Masato Okamoto, Tetsuya Oshikawa, Sachiko Furuichi, Osamu Takeuchi, Sachiko Akashi, Shuzo Matsubara, Mitsunobu Sato, Go Ohe, Yoshiki Ryoma
Publikováno v:
Journal of the National Cancer Institute. 95(4)
Background: The streptococcal agent OK-432 has been used for immunotherapy of head and neck cancer, among other malignancies, but its mechanism of action is unknown. Because the Toll-like receptor 4 (TLR4)/MD-2 complex is important in enabling the ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a4410bc1c8e7f86014a62437a7f2f1f
https://pubmed.ncbi.nlm.nih.gov/12591988
https://pubmed.ncbi.nlm.nih.gov/12591988